Gyre Therapeutics Inc. (GYRE)vsRevolution Medicines Inc (RVMD)
GYRE
Gyre Therapeutics Inc.
$4.30
+0.94%
HEALTHCARE · Cap: $470.79M
RVMD
Revolution Medicines Inc
$176.35
-2.41%
HEALTHCARE · Cap: $41.76B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates 80% more annual revenue ($197.56M vs $109.82M). RVMD leads profitability with a 0.0% profit margin vs -19.3%. GYRE earns a higher WallStSmart Score of 25/100 (F).
GYRE
Avoid25
out of 100
Grade: F
RVMD
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GYRE.
Margin of Safety
+89.8%
Fair Value
$1883.88
Current Price
$176.35
$1707.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 166.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -13.3% — below average capital efficiency
Revenue declined 2.1%
Trading at 15.9x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GYRE
The strongest argument for GYRE centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : GYRE
The primary concerns for GYRE are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
GYRE profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.
GYRE carries more volatility with a beta of 4.92 — expect wider price swings.
GYRE is growing revenue faster at -2.1% — sustainability is the question.
GYRE generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
GYRE scores higher overall (25/100 vs 23/100). RVMD offers better value entry with a 89.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary platform that harmoniously combines gene therapy with precision medicine, Gyre is focused on delivering innovative solutions to address significant unmet medical needs. With a robust pipeline and a strong commitment to scientific excellence, the company is well-positioned for sustained growth and impact in the biopharmaceutical sector. Its strategic collaborations and ongoing research and development efforts underscore Gyre's potential to revolutionize treatment paradigms and improve patient outcomes in challenging health conditions.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?